xofigo
bayer ag - radium (223ra) dichloride - prostatiset kasvaimet - terapeuttiset radiofarmaseuttiset valmisteet - xofigo on tarkoitettu aikuisilla, joilla on kastrointuntuvaa eturauhassyöpää, oireeton luumetastaaseja eikä tunnettuja viskeraalisia metastaaseja.
akeega
janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - eturauhasen kasvaimet, kastraatio-resistentin - antineoplastiset aineet - treatment of adult patients with prostate cancer.
zytiga
janssen-cilag international n.v. - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - zytiga on merkitty prednisoni tai prednisoloni:metastasoituneen kastraation kastraatioresistentin eturauhassyövän aikuiset miehet, jotka ovat oireettomia tai lievästi oireileva jälkeen epäonnistuminen androgeenideprivaatiohoito joille kemoterapiaa ei ole vielä kliinisesti indicatedthe metastasoituneen kastraation kestävä eturauhassyövän hoitoon aikuisilla miehillä, joiden tauti on edennyt, tai kun docetaxel perustuu solunsalpaajahoito.
abiraterone accord
accord healthcare s.l.u. - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone mylan
mylan ireland limited - abirateroniasetaatti - prostatiset kasvaimet - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone krka
krka, d.d., novo mesto - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
abiraterone ratiopharm 500 mg tabletti, kalvopäällysteinen
teva b.v. - abiraterone acetate - tabletti, kalvopäällysteinen - 500 mg - abirateroni
abiraterone stada 500 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - abiraterone acetate - tabletti, kalvopäällysteinen - 500 mg - abirateroni
abiraterone orion 500 mg tabletti, kalvopäällysteinen
orion corporation - abiraterone acetate - tabletti, kalvopäällysteinen - 500 mg - abirateroni
abirateron sandoz 1000 mg tabletti, kalvopäällysteinen
sandoz a/s - abiraterone acetate - tabletti, kalvopäällysteinen - 1000 mg - abirateroni